Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 2, 2009, Pages

  Angoulvant, Denis ^a   Fazel, Shafie ^a   Weisel, Richard D ^a   Lai, Teresa Y Y ^a   Fedak, Paul W ^a   Chen, Liwen ^a   Rafati, Shahin ^a   Seneviratne, Charit K ^a   Degousee, Norbert ^a   Li, Ren Ke ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL 6 MOUSE; CELL BASED GENE THERAPY; CELL TRANSPLANTATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART DILATATION; HEART FUNCTION; HEART INFARCTION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; STROMA CELL;

EID: 58649101874     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.08.031     Document Type: Article

References (29)

1. Fazel S., Cimini M., Chen L., Li S., Angoulvant D., Fedak P., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 116 (2006) 1865-1877
2. Kim C., Li R.K., Li G., Zhang Y., Weisel R.D., and Yau T.M. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg 83 (2007) 640-646
3. Yau T.M., Kim C., Li G., Zhang Y., Fazel S., Spiegelstein D., et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg 83 (2007) 1110-1119
4. Fedak P.W., Szmitko P.E., Weisel R.D., Altamentova S.M., Nili N., Ohno N., et al. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J Thorac Cardiovasc Surg 130 (2005) 1430-1439
5. Peterson J.T., Li H., Dillon L., and Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46 (2000) 307-315
6. Fedak P.W., Altamentova S.M., Weisel R.D., Nili N., Ohno N., Verma S., et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 284 (2003) H626-H634
7. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
8. Webb C.S., Bonnema D.D., Ahmed S.H., Leonardi A.H., McClure C.D., Clark L.L., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114 (2006) 1020-1027
9. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 20034;107:618-25.
10. Spinale F.G., Escobar G.P., Hendrick J.W., Clark L.L., Camens S.S., Mingoia J.P., et al. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther 318 (2006) 966-973
11. Hudson M.P., Armstrong P.W., Ruzyllo W., Brum J., Cusmano L., Krzeski P., et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 48 (2006) 15-20
12. Jayasankar V., Woo Y.J., Bish L.T., Pirolli T.J., Berry M.F., Burdick J., et al. Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 110 (2004) II180-II186
13. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110 (2004) 2401-2409
14. Leco K.J., Waterhouse P., Sanchez O.H., Gowing K.L., Poole A.R., Wakeham A., et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 108 (2001) 817-829
15. Tian H., Cimini M., Fedak P.W.M., Altamentova S., Fazel S., Huang M.L., et al. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 43 (2007) 733-743
16. Kiani C., Lee V., Cao L., Chen L., Wu Y., Zhang Y., et al. Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 354 Pt 1 (2001) 199-207
17. Degousee N., Ghomashchi F., Stefanski E., Singer A., Smart B.P., Borregaard N., et al. Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem 277 (2002) 5061-5073
18. Fedak P.W., Moravec C.S., McCarthy P.M., Altamentova S.M., Wong A.P., Skrtic M., et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 113 (2006) 238-245
19. Wijsman J.H., Jonker R.R., Keijzer R., van d V., Cornelisse C.J., and van Dierendonck J.H. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 41 (1993) 7-12
20. Fazel S., Chen L., Weisel R.D., Angoulvant D., Seneviratne C., Fazel A., et al. Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg 130 (2005) 1310
21. Liu T.B., Fedak P.W., Weisel R.D., Yasuda T., Kiani G., Mickle D.A., et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol 287 (2004) H2840-H2849
22. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9 (2003) 1195-1201
23. Yau T.M., Kim C., Li G., Zhang Y., Weisel R.D., and Li R.K. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 112 (2005) I123-I128
24. Yasuda T., Weisel R.D., Kiani C., Mickle D.A., Maganti M., and Li R.K. Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction. J Thorac Cardiovasc Surg 129 (2005) 904-911
25. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20 (2006) 661-669
26. Mizuno T., Yau T.M., Weisel R.D., Kiani C.G., and Li R.K. Elastin stabilizes an infarct and preserves ventricular function. Circulation 112 (2005) I81-I88
27. Sun M., Dawood F., Wen W.H., Chen M., Dixon I., Kirshenbaum L.A., et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110 (2004) 3221-3228
28. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435 (1998) 39-44
29. Woessner Jr. J.F. That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin Invest 108 (2001) 799-800